These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19412196)

  • 1. Assessing infection risk with biologic agents in RA: methodological challenges.
    Fisher MC; Greenberg JD
    Nat Rev Rheumatol; 2009 May; 5(5):288-91. PubMed ID: 19412196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious infections with antirheumatic therapy: are biologicals worse?
    Winthrop KL
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii54-7. PubMed ID: 17038474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.
    Franklin JP; Symmons DP; Silman AJ
    Ann Rheum Dis; 2005 May; 64(5):657-8. PubMed ID: 15834052
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis.
    Katikireddi VS; Whittle SL; Hill CL
    Int J Rheum Dis; 2010 Feb; 13(1):12-26. PubMed ID: 20374381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.
    Ranza R; de la Vega MC; Laurindo IMM; Gómez MG; Titton DC; Kakehasi AM; Brigante A; Benitez A; Ranzolin A; Granel A; Cappuccio AM; Quinteros A; Hayata ALS; Smichowski A; Duarte ÂLBP; Kahlow BS; Andia CS; Brenol CV; Velozo E; Mussano E; Soriano ER; Christopoulos GB; da Rocha Castelar Pinheiro G; de Castro GRW; Casado G; da Silveira Carvalho HM; Exeni IE; da Silveira IG; Petkovic I; Pereira IA; da Costa IP; Rosa JE; Miranda JRS; de Moraes JCB; Bertolo MB; Buhl M; Lázaro MA; da Sauma MFLC; de Medeiros Pinheiro M; Díaz M; de Vechi MVSS; Cerda OL; Astesana P; Curi PF; Louzada-Jr P; Teodoro RB; Toledo RA; Papasidero S; Valim V; Fernandes V; Saurit V; Bianchi WA; ; de Melo Costa Pinto R; Descalzo MA; Gomez-Reino JJ
    Clin Rheumatol; 2019 Aug; 38(8):2129-2139. PubMed ID: 31016578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.
    Patkar NM; Teng GG; Curtis JR; Saag KG
    Curr Opin Rheumatol; 2008 May; 20(3):320-6. PubMed ID: 18388525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV; Sanmartí R; Cañete JD
    Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
    Keystone EC
    J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Thompson AE; Rieder SW; Pope JE
    Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.
    Kourbeti IS; Ziakas PD; Mylonakis E
    Clin Infect Dis; 2014 Jun; 58(12):1649-57. PubMed ID: 24647016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections in patients with rheumatoid arthritis treated with biologic agents.
    Listing J; Strangfeld A; Kary S; Rau R; von Hinueber U; Stoyanova-Scholz M; Gromnica-Ihle E; Antoni C; Herzer P; Kekow J; Schneider M; Zink A
    Arthritis Rheum; 2005 Nov; 52(11):3403-12. PubMed ID: 16255017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor inhibitors and infection complications.
    Crawford M; Curtis JR
    Curr Rheumatol Rep; 2008 Oct; 10(5):383-9. PubMed ID: 18817643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Singh JA; Cameron C; Noorbaloochi S; Cullis T; Tucker M; Christensen R; Ghogomu ET; Coyle D; Clifford T; Tugwell P; Wells GA
    Lancet; 2015 Jul; 386(9990):258-65. PubMed ID: 25975452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
    Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
    Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.